These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 2730708)

  • 21. Glycoxidized HDL, HDL enriched with oxidized phospholipids and HDL from diabetic patients inhibit platelet function.
    Lê QH; El Alaoui M; Véricel E; Ségrestin B; Soulère L; Guichardant M; Lagarde M; Moulin P; Calzada C
    J Clin Endocrinol Metab; 2015 May; 100(5):2006-14. PubMed ID: 25794249
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypochlorite modified LDL are a stronger agonist for platelets than copper oxidized LDL.
    Volf I; Roth A; Cooper J; Moeslinger T; Koller E
    FEBS Lett; 2000 Oct; 483(2-3):155-9. PubMed ID: 11042272
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low-density lipoproteins inhibit the Na+/H+ antiport in human platelets. A novel mechanism enhancing platelet activity in hypercholesterolemia.
    Nofer JR; Tepel M; Kehrel B; Wierwille S; Walter M; Seedorf U; Zidek W; Assmann G
    Circulation; 1997 Mar; 95(6):1370-7. PubMed ID: 9118502
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhancement of platelet aggregation by low-density lipoproteins from IDDM patients.
    Watanabe J; Wohltmann HJ; Klein RL; Colwell JA; Lopes-Virella MF
    Diabetes; 1988 Dec; 37(12):1652-7. PubMed ID: 3192039
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipoproteins and the haemostatic system in atherothrombotic disorders.
    Miller GJ
    Baillieres Clin Haematol; 1994 Sep; 7(3):713-32. PubMed ID: 7841607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modified forms of low density lipoprotein affect platelet aggregation in vitro.
    Aviram M
    Thromb Res; 1989 Mar; 53(6):561-7. PubMed ID: 2734732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibitory effects of in vivo oxidized high-density lipoproteins on platelet aggregation: evidence from patients with abetalipoproteinemia.
    Calzada C; Véricel E; Colas R; Guillot N; El Khoury G; Drai J; Sassolas A; Peretti N; Ponsin G; Lagarde M; Moulin P
    FASEB J; 2013 Jul; 27(7):2855-61. PubMed ID: 23507868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LDL-platelet interaction under oxidative stress induces macrophage foam cell formation.
    Aviram M
    Thromb Haemost; 1995 Jul; 74(1):560-4. PubMed ID: 8578524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibitor analysis of LDL-induced platelet aggregation.
    Vlasova II; Azizova OA; Lopukhin YuM
    Biochemistry (Mosc); 1997 Mar; 62(3):307-11. PubMed ID: 9275303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effects of plasma very low density lipoprotein, low density lipoprotein and high density lipoprotein on platelet aggregation in endogenous hypertriglyceridemia].
    Deng Z; Liu B; Zhou J; Zhang Z; Liu Y; Bai H
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Oct; 34(4):704-7. PubMed ID: 14619587
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of (E)-4-hydroxy-2-nonenal in platelet activation by low density lipoprotein and iron.
    Selley ML; Bartlett MR; Czeti AL; Ardlie NG
    Atherosclerosis; 1998 Sep; 140(1):105-12. PubMed ID: 9733221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The effect of lipid peroxidation-modified lipoproteins on thrombocyte aggregation].
    Azizova OA; Vlasova II
    Biull Eksp Biol Med; 1993 Nov; 116(11):485-7. PubMed ID: 8312535
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oxidation of low density lipoproteins in the pathogenesis of atherosclerosis.
    Holvoet P; Collen D
    Atherosclerosis; 1998 Apr; 137 Suppl():S33-8. PubMed ID: 9694539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of dietary fatty acids on membrane fluidity and activation of rat platelets.
    Heemskerk JW; Feijge MA; Kalafusz R; Hornstra G
    Biochim Biophys Acta; 1989 Aug; 1004(2):252-60. PubMed ID: 2752022
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Arachidonate metabolism, 5-hydroxytryptamine release and aggregation in human platelets activated by palmitaldehyde acetal phosphatidic acid.
    Brammer JP; Maguire MH
    Br J Pharmacol; 1984 May; 82(1):61-72. PubMed ID: 6428500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activated platelets contribute to oxidized low-density lipoproteins and dysfunctional high-density lipoproteins through a phospholipase A2-dependent mechanism.
    Blache D; Gautier T; Tietge UJ; Lagrost L
    FASEB J; 2012 Feb; 26(2):927-37. PubMed ID: 22042222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Platelet interaction with high and low density lipoproteins.
    Aviram M; Brook JG
    Atherosclerosis; 1983 Mar; 46(3):259-68. PubMed ID: 6847742
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High density lipoprotein inhibits platelet 12-lipoxygenase activity.
    Fujimoto Y; Tsunomori M; Muta E; Yamamoto T; Nishida H; Sakuma S; Fujita T
    Res Commun Mol Pathol Pharmacol; 1994 Sep; 85(3):355-8. PubMed ID: 7827811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effect of low-density lipoprotein on enhanced microviscosity and aggregation of platelet].
    Chen SH
    Zhonghua Yi Xue Za Zhi; 1987 May; 67(5):266-8. PubMed ID: 3115525
    [No Abstract]   [Full Text] [Related]  

  • 40. Enhancement of platelet functions by low density lipoproteins.
    Surya II; Gorter G; Mommersteeg M; Akkerman JW
    Biochim Biophys Acta; 1992 Nov; 1165(1):19-26. PubMed ID: 1420343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.